Similar articles

• [Effect of vitamin D metabolites on mineralization of bone tissue and phosphocalcium metabolism disorders in the course of vitamin D deficiency osteomalacia].

  Bordier P, Miravet L, Marie P, Guéris J, Rousselet F, Norman A, Rasmussen H, Ryckewaert A. Bordier P, et al. Rev Rhum Mal Osteoartic. 1978 Apr;45(4):241-8. Rev Rhum Mal Osteoartic. 1978. PMID: 353964 Clinical Trial. French. No abstract available.
• Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.

  Malluche HH, Goldstein DA, Massry SG. Malluche HH, et al. Contrib Nephrol. 1980;18:98-104. doi: 10.1159/000403277. Contrib Nephrol. 1980. PMID: 7353383 No abstract available.
• Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.

  Coburn JW, Brickman AS. Coburn JW, et al. Adv Exp Med Biol. 1978;103:473-86. doi: 10.1007/978-1-4684-7758-0_48. Adv Exp Med Biol. 1978. PMID: 362852 Review. No abstract available.
• Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.

  Chesney RW, Hamstra A, Jax DK, Mazess RB, DeLuca HF. Chesney RW, et al. Contrib Nephrol. 1980;18:55-71. doi: 10.1159/000403273. Contrib Nephrol. 1980. PMID: 7353380 No abstract available.
• Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

  Massry SG, Goldstein DA, Malluche HH. Massry SG, et al. Kidney Int. 1980 Oct;18(4):409-18. doi: 10.1038/ki.1980.154. Kidney Int. 1980. PMID: 7014981 Review. No abstract available.